Search results for "Diabetic neuropathy"

showing 10 items of 33 documents

Altered Semmes–Weinstein monofilament test results are associated with oxidative stress markers in type 2 diabetic subjects

2017

Abstract Background Different lines of evidence suggest that oxidative stress (OS) is implicated in the pathogenesis of diabetic neuropathy. The Semmes–Weinstein monofilament (SWM) test is an efficient tool for evaluating diabetic polyneuropathy and diabetic foot. In this study, we analyzed the association between OS markers and altered SWM test results in type 2 diabetes (T2DM) patients. Methods Seventy T2DM patients were studied and 34 showed altered SWM results. The clinical and biochemical parameters were determined using standardized methods. Levels of oxidized glutathione (GSSG) and malondialdehyde (MDA) were measured in circulating mononuclear cells using high-performance liquid chro…

0301 basic medicineMalemedicine.medical_specialtyGlutathione systemDiabetic neuropathySemmes–Weinstein monofilament testlcsh:MedicineType 2 diabetesmedicine.disease_causeGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMalondialdehydeType 2 diabetes mellitusmedicinePeripheral polyneuropathyHumansAgedAnthropometryGlutathione Disulfidebusiness.industryResearchlcsh:RGeneral Medicinemedicine.diseaseMalondialdehydeDiabetic footHealthy VolunteersOxidative Stress030104 developmental biologyEndocrinologychemistryDiabetes Mellitus Type 2Glutathione disulfideFemaleHemoglobinbusinessPolyneuropathy030217 neurology & neurosurgeryOxidative stressBiomarkersJournal of Translational Medicine
researchProduct

Effects of acetyl-l-carnitine in diabetic neuropathy and other geriatric disorders

2018

A long history of diabetes mellitus and increasing age are associated with the onset of diabetic neuropathy, a painful and highly disabling complication with a prevalence peaking at 50% among elderly diabetic patients. Acetyl-l-carnitine (ALC) is a molecule derived from the acetylation of carnitine in the mitochondria that has an essential role in energy production. It has recently been proposed as a therapy to improve the symptoms of diabetic neuropathy. ALC is widely distributed in mammalian tissues, including the brain, blood–brain barrier, brain neurons, and astrocytes. Aside from its metabolic activity, ALC has demonstrated cytoprotective, antioxidant, and antiapoptotic effects in the …

0301 basic medicineNervous systemAgingmedicine.medical_specialtyDiabetic neuropathyDiabetic neuropathyPainNeurotrophic effectAcetyl-l-carnitine; Analgesia; Diabetic neuropathy; Neurotrophic effect; Aging; Geriatrics and GerontologyNO03 medical and health sciences0302 clinical medicineDiabetic NeuropathiesAlzheimer DiseaseInternal medicineDiabetes mellitusmedicineHumansCarnitineAcetyl-l-carnitine; Analgesia; Diabetic neuropathy; Neurotrophic effectAcetylcarnitineAcetyl-l-carnitine Diabetic neuropathy Analgesia Neurotrophic effectAgedAnalgesicsbusiness.industryGlutamate receptormedicine.diseaseMitochondriaAcetyl-l-carnitine030104 developmental biologyNerve growth factorEndocrinologymedicine.anatomical_structureAnalgesiaGeriatrics and GerontologyAlzheimer's diseaseAcetylcarnitinebusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Induction of vascular endothelial growth factor release by transcutaneous frequency modulated neural stimulation in diabetic polyneuropathy

2008

Background: Pharmacological treatment for diabetic polyneuropathy (DP) has shown limited benefit; frequency-modulated electrical stimulation (FREMS) has shown positive results in pain control and nerve conduction velocity in DP. Objective: To investigate the effects of FREMS vs transcutaneous electrical nerve stimulation (TENS) on the release of vascular endothelial growth factor (VEGF) in Type 2 diabetic and in non-diabetic subjects. Methods: 10 non-diabetic [mean age 37±5 yr; females (F)/males (M): 6/4] and 10 Type 2 diabetic subjects (mean age 52±6 yr; F/M: 5/5) with DP underwent TENS (for 10 min) followed by 30 min interval without electrical stimulation, and then FREMS (for 10 min) ove…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyDiabetic neuropathyEndocrinology Diabetes and MetabolismNeural ConductionAction PotentialsPainElectric Stimulation TherapyStimulationTranscutaneous electrical nerve stimulationNerve conduction velocitylaw.inventionchemistry.chemical_compoundEndocrinologyDiabetic NeuropathiesForearmlawInternal medicineVasa nervorumHumansPain ManagementMedicineMotor Neuronsbusiness.industryMicroangiopathyMiddle Agedmedicine.diseaseVascular endothelial growth factorEndocrinologymedicine.anatomical_structurechemistryTranscutaneous Electric Nerve StimulationFemalebusiness
researchProduct

Serum levels of substance P are decreased in patients with type 1 diabetes.

2000

Morphological and immunohistochemical studies in diabetic subjects have shown a depletion of the neuropeptide substance P (SP) in the central and peripheral nervous system. This is the first study investigating serum levels of substance P in type 1 diabetes patients (n=50) and controls (n=75) by means of an enzyme immunoassay. The serum level of SP was significantly decreased in the diabetic group compared to the control group (10.12+/-0.29 vs. 12.25+/-0.38 pg/ml; p<0.0001). In diabetic patients, there was no correlation of substance P levels with age, serum creatinine, albuminuria, total cholesterol, HDL- or LDL-cholesterol, triglycerides, HbA1c, type or duration of diabetes and gender. Fu…

AdultMalemedicine.medical_specialtyDiabetic neuropathyAdolescentEndocrinology Diabetes and MetabolismSubstance PSubstance PImmunoenzyme Techniqueschemistry.chemical_compoundEndocrinologyReference ValuesInternal medicineDiabetes mellitusBlood plasmaInternal MedicinemedicineHumansAgedType 1 diabetesCreatininebusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePeripheral neuropathyEndocrinologyCholesterolDiabetes Mellitus Type 1chemistryAlbuminuriaFemalemedicine.symptombusinessExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Cardiovascular autonomic neuropathy in type 1 diabetic patients with and without peripheral neuropathy.

1998

One hundred Type 1 diabetic patients (54 men, 46 women) mean age 28.9 +/- 8.4 years, were selected from among individuals referred to our hospital, with no previous diagnosis of diabetic chronic complications including diabetic neuropathy. After clinical and physical examinations, subjects were divided into two groups: with (n = 37) and without (n = 63) peripheral neuropathy. The percentage of subjects with cardiovascular autonomic neuropathy (AN), diagnosed by positive results to at least two of the five cardiovascular tests (Valsalva ratio, EI ratio, 30/15 ratio, blood-pressure response to standing up and handgrip test), was 40%: 72.9% in the group with peripheral neuropathy and 20.6% in …

AdultMalemedicine.medical_specialtyDiabetic neuropathyAdolescentValsalva ManeuverEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPostureBlood PressureAutonomic Nervous SystemGastroenterologyEndocrinologyDiabetic NeuropathiesDiabetes mellitusInternal medicineInternal MedicinemedicineValsalva maneuverAlbuminuriaHumansPeripheral NervesType 1 diabetesProteinuriaDiabetic RetinopathyHand Strengthbusiness.industryPeripheral Nervous System DiseasesGeneral MedicineMiddle Agedmedicine.diseaseSurgeryPeripheral neuropathyDiabetes Mellitus Type 1Autonomic Nervous System DiseasesMicroalbuminuriaFemalemedicine.symptombusinessRetinopathyDiabetes research and clinical practice
researchProduct

Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study.

2017

Different sensory profiles in diabetic distal symmetrical sensory-motor polyneuropathy (DSPN) may be associated with pain and the responsiveness to analgesia. We aimed to characterize sensory phenotypes of patients with painful and painless diabetic neuropathy and to assess demographic, clinical, metabolic, and electrophysiological parameters related to the presence of neuropathic pain in a large cohort of well-defined DSPN subjects. This observational cross-sectional multi-center cohort study (performed as part of the ncRNAPain EU consortium) of 232 subjects with nonpainful (n = 74) and painful (n = 158) DSPN associated with diabetes mellitus of type 1 and 2 (median age 63 years, range 21-…

AdultMalemedicine.medical_specialtyDiabetic neuropathyAnalgesic030209 endocrinology & metabolismNeurological examinationCohort Studies03 medical and health sciencesPolyneuropathiesYoung Adult0302 clinical medicineDiabetic NeuropathiesRisk FactorsInternal medicineDiabetes mellitusmedicineHumansAgedAged 80 and overNeurologic Examinationmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseAnesthesiology and Pain MedicineCross-Sectional StudiesPhenotypeNeurologyNeuropathic painPhysical therapyNeuralgiaPain catastrophizingFemaleNeurology (clinical)businessPolyneuropathy030217 neurology & neurosurgeryCohort studyPain
researchProduct

Simultaneous Pancreas Kidney Transplantation Improves Cardiovascular Autonomic Neuropathy with Improved Valsalva Ratio as the Most Precocious Test

2020

Background. Simultaneous pancreas-kidney (SPK) transplantation is a proven option of treatment for patients with type 1 diabetes mellitus (T1DM) and related end-stage renal disease. There is discrepancy between the results of different studies about the impact of prolonged normalization of glucose metabolism achieved by SPK on the course of diabetic complications including severe forms of diabetic neuropathy. The objective of the study was to evaluate the prevalence of cardiovascular autonomic neuropathy (CAN) in patients undergoing SPK transplantation and its evolution 10 years after transplantation. Methods. Prospective study of 81 patients transplanted in a single center from year 2002 t…

AdultMalemedicine.medical_specialtyDiabetic neuropathyComplicationsArticle SubjectEndocrinology Diabetes and MetabolismSingle CenterAutonomic Nervous SystemDiseases of the endocrine glands. Clinical endocrinologyAssociationTECNOLOGIA ELECTRONICAEndocrinologyTrial/EpidemiologyDiabetic NeuropathiesInternal medicineDiabetes mellitusDiagnosismedicineAutonomic reflexRisk-FactorsHumansDiabetes-MellitusProspective StudiesMortalityProspective cohort studyInterventionsType 1 diabetesbusiness.industryGraft SurvivalMiddle Agedmedicine.diseaseRC648-665Kidney TransplantationTransplantationBlood pressureDiabetes Mellitus Type 1Treatment OutcomeDysfunctionCardiologyClinical StudyFemaleStatementPancreas TransplantationbusinessFollow-Up StudiesJournal of Diabetes Research
researchProduct

Electrically stimulated axon reflexes are diminished in diabetic small fiber neuropathies.

2004

Axon reflex mediated flare depends on the density and the function of cutaneous C-fibers and may be impaired in diabetic neuropathy. We induced neurogenic axon reflex flare by intracutaneous electrical stimulation and analyzed size and intensity of the flare on the dorsum of the foot and ventral thigh with laser Doppler imaging (LDI). We investigated 12 diabetic subjects with small fiber neuropathies (SFNs), 5 diabetic subjects without neuropathy (NO-Ns), and 14 healthy control subjects. Five of the normal subjects were reassessed after 12 months. In comparing patients with SFN to control subjects, we found that SFN flare size but not the intensity of vasodilation (flux) was reduced on the …

AdultMalemedicine.medical_specialtyDiabetic neuropathyEndocrinology Diabetes and MetabolismNeural ConductionPainStimulationVasodilationNerve FibersDiabetic NeuropathiesReference ValuesDiabetes mellitusInternal medicineReflexInternal MedicinemedicineHumansNeurons AfferentAxonSkinbusiness.industryPeroneal NerveMiddle Agedmedicine.diseaseAxonsElectric StimulationIntensity (physics)medicine.anatomical_structureEndocrinologyReflexAxon reflexFemalebusinessDiabetes
researchProduct

Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.

2003

The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years. After 4 weeks of treatment, pain, as measured using the Brief Pain Inventory, was decreased compared with baseline. Treatment was generally well tolerated. This study indicates that gabapentin should be considered as a treatment option for the neuropathic pain of Fabry disease.

AdultMalemedicine.medical_specialtyDiabetic neuropathyGabapentinAdolescentCyclohexanecarboxylic Acidsmedicine.medical_treatmentAcetatesGeneticsmedicineHumansBrief Pain InventoryAminesGenetics (clinical)gamma-Aminobutyric AcidPain Measurementbusiness.industryVascular diseaseEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryAnticonvulsantTreatment OutcomeAnesthesiaNeuropathic painFabry DiseaseNeuralgiaAnticonvulsantsGabapentinbusinessmedicine.drugJournal of inherited metabolic disease
researchProduct

Predictive model to identify the risk of losing protective sensibility of the foot in patients with diabetes mellitus

2019

Diabetic neuropathy is defined as the presence of symptoms and signs of peripheral nerve dysfunction in diabetics. The aim of this study is to develop a predictive logistic model to identify the risk of losing protective sensitivity in the foot. This descriptive cross‐sectional study included 111 patients diagnosed with diabetes mellitus. Participants completed a questionnaire designed to evaluate neuropathic symptoms, and multivariate analysis was subsequently performed to identify an optimal predictive model. The explanatory capacity was evaluated by calculating the R (2) coefficient of Nagelkerke. Predictive capacity was evaluated by calculating sensitivity, specificity, and estimation o…

AdultMalemedicine.medical_specialtyDiabetic neuropathyMultivariate analysismellitus diabetesDermatologyLogistic regressionRisk AssessmentSeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDiabetic NeuropathiesPeripheral nerveRisk FactorsInternal medicineDiabetes mellitusClinical Decision RulesmedicineHumansIn patient030212 general & internal medicineAgedAged 80 and overbusiness.industryOriginal ArticlesMiddle Agedmedicine.diseasepredictive modelsDiabetic footdiabetic neuropathyDiabetic FootCross-Sectional StudiesDiabetes Mellitus Type 1Logistic ModelsDiabetes Mellitus Type 2Sensory ThresholdsSurgeryFemalebusinessFoot (unit)diabetic foot
researchProduct